Business Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Business Analysis

Pfizer Plans Additional Cost Cutting

October 19, 2006

ePT--the Electronic Newsletter of Pharmaceutical Technology

New York, NY (Oct. 19)-Pfizer, Inc. plans to implement a new company-wide cost-cutting initiative in 2007 as part of strategy to improve operating performance. The cuts are in addition to a previous cost-reduction program that Pfizer launched in 2005.

AnorMED accepts Genzyme's Offer of US $13.50 a Share

October 12, 2006

ePT--the Electronic Newsletter of Pharmaceutical Technology

Langley, BC, Canada (Oct. 10)-AnorMED Inc. has determined that Genzyme's US $580 million offer to acquire all outstanding AnorMED shares at US $13.50 a share is a "superior proposal."

Merck KGaA to Acquire Majority Stake in Serono for $13.3 Billion

September 21, 2006

ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck KGaA has agreed to buy a majority stake in the European biotechnology company Serono SA for CHF 16.6 billion ($13.3 billion).

PhRMA Names New Chairman

September 21, 2006

ePT--the Electronic Newsletter of Pharmaceutical Technology

Kevin Sharer has become chairman of the board of the Pharmaceutical Research and Manufacturers of America upon the resignation of Peter R. Dolan.

Chemir Launches IQsynthesis

September 14, 2006

ePT--the Electronic Newsletter of Pharmaceutical Technology

Chemir Analytical Services has launched IQsynthesis, formerly known as Gateway Chemical Technology, Inc. Chemir acquired Gateway Chemical Technology, which provides custom synthesis and process development services, in May 2006.

Stage Fright: The Risks and Benefits of Moving Forward

September 2, 2006

Pharmaceutical Technology

For once, casting originators against generic players might end up strengthening the industry across the board.

Between Rocks and Hard Places: The Southeast Asian Pharmaceutical Industry at a Juncture

September 2, 2006

Pharmaceutical Technology

Mid-size companies are forcing through their market positions by developing their niche competencies and their flexibilities to be recognized as serious market contenders.

Healthy Contrasts: A Look at Markets and Health Systems Across the ASEAN Region

September 2, 2006

Pharmaceutical Technology

The overall market size of the Southeast Asia region totals $7 billion, with a projected compound annual growth rate of about 13% through 2010.

T cells for patient-specific cancer treatment

April 1, 2010
Pharmaceutical Technology Europe

T cell therapy is an investigational approach that is being assessed for the patient?specific treatment of cancer.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here